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Abstracts / International Journal of Surgery 36 (2016) S31eS132 S53Conclusion: Breast reconstruction following mastectomy is associated
with high levels of patient satisfaction, particularly among those who have
undergone delayed reconstruction. Higher complication rates were noted
in patients who received post mastectomy radiation. Breast reconstruction
should be discussed with patients undergoing mastectomy.http://dx.doi.org/10.1016/j.ijsu.2016.08.112
0768: MANAGEMENT OF AROMATASE INHIBITOR-INDUCED BONE LOSS
IN BREAST CANCER PATIENTS
N. Husnoo 1,*, M. Shaan Goonoo 2, S. Abbas 3. 1Barnsley District General
Hospital, Barnsley, UK; 2Royal Blackburn Hospital, Blackburn, UK;
3Kensington Partnership, Bradford, UK.
Aim: Aromatase-inhibitors (AIs), used in breast cancer treatment, increase
bone loss rate. This audit evaluates adherence to the “Guidance for the
Management of Breast Cancer Treatment-Induced Bone Loss” (UK expert
group consensus, 2008) in patients on AIs at a large general practice.
Method: Data was retrospectively collected on all patients registered at
our practice currently, or previously, on an AI for breast cancer treatment.
Result: 12 of the 14 patients identiﬁed were eligible for a baseline done
density screen upon AI initiation. 25% (n ¼ 3) did not get screened and
therefore received no subsequent fracture-risk management. 9 had a
baseline screen and appropriate drug therapy. Seven required repeat two-
yearly scans but only three were scanned. Baseline screens were mainly
requested by breast specialists (n ¼ 5) or by the general practitioner at the
breast specialists' request (n ¼ 3).
Conclusion: Management of AI-induced bone loss in our patients needs
improvement. To our knowledge no study has been performed in the UK to
assess adherence to bone loss management guidance in breast cancer
patients. Larger centres should audit their practice to ascertain the
magnitude of the problem. It should be clariﬁed how the responsibility of
bone loss management can be shared between primary and secondary
care.http://dx.doi.org/10.1016/j.ijsu.2016.08.113
0838: UPTAKE OF RISK REDUCING SURGERY IN BRCA GENE MUTATION
CARRIERS IN WALES
J. Long 1,*, T. Evans 1, D. Bailey 3, M. Lewis 3, K. Gower-Thomas 2, A. Murray 1.
1University Hospital of Wales, Cardiff, UK; 2Royal Glamorgan Hospital,
Llantrisant, UK; 3University of South Wales, Pontypridd, UK.
Introduction:Women who inherit a mutated copy of the BRCA gene have
a higher lifetime risk of developing breast cancer. No large epidemiological
studies exist looking at BRCA carriers in the UK.
Method: All patients in Wales with BRCA1/BRCA2 mutation between
1995e2014 were identiﬁed from a prospectively gathered database.
Retrospective analysis of genetics case-notes was performed.
Result: 412 living females, median age 43(18e81) at time of testing, were
included.
Of 202 womenwho underwent diagnostic testing (symptomatic) 178 (88%)
had breast cancer, 43 had ovarian cancer and 19 had both at time of testing.
50 women from the diagnostic group who had not already undergone
bilateral mastectomies (29%) subsequently underwent risk-reducing
mastectomies (RRM); 79 women who had breast-conserving surgery for
cancer prior to testing did not have subsequent RRM.
210 women underwent predictive testing (family history, asymptomatic).
50% of predictive tests were carried out in the last 4 years. 10 women(5%)
developed breast cancer after testing, none had previously undergone risk-
reducing surgery. 64 patients from predictive group (30%) underwent
RRM.
Conclusion: This unique study of BRCA carriers in Wales shows consid-
erable variation in uptake of risk-reducing surgery with signiﬁcant im-
plications for service allocation and screening demands for this high-risk
group.http://dx.doi.org/10.1016/j.ijsu.2016.08.114
0933: AUDIT ON USE OF ONCOTYPE DX (ODX) TO GUIDE MULTIDISCI-
PLINARY TEAM (MDT) REGARDING CHEMOTHERAPY IN EARLY BREAST
CANCER
J. Keay*, A. Abbas, J. Kokan, C. Roshanlall. East Cheshire Trust, Macclesﬁeld,
UK.
Background: ODX assay helps a breast MDT decide if patients with early
breast cancer will beneﬁt from chemotherapy. Costing around £2,500,
NICE has issued guidance for MDTs on the option to use ODX. On average
six chemotherapy sessions are needed for breast cancer (£4,000 per ses-
sion). In our department this test is only offered to early breast cancer
patients and our aim was to assess how it guided our MDT regarding
chemotherapy.
Method: All the patients who had an ODX assay were identiﬁed
(2014e2015). Patients who did not have an ODX assay but had a Not-
tingham prognostic index 3.4 were also identiﬁed (2013e2014). MDT
outcome notes were retrospectively studied to note if ODX aided the MDT
decision regarding chemotherapy.
Result: 39 patients had ODX assay performed and most had Grade 3 tu-
mours (48.7%). It informed decision in all patients except one (2.5%). In 23
patients (59%) recurrence score was low (<18) and guided MDT that
chemotherapy will not provide any treatment beneﬁt. 31 patients (79%)
had radiotherapy and all had hormone therapy.
Conclusion: ODX test prevented chemotherapy in more than half of our
early breast cancer patients. In addition it's economical to use, saving the
NHS about £20,000 per patient.http://dx.doi.org/10.1016/j.ijsu.2016.08.115
0994: INTRODUCTION OF THE NEW GUIDELINES ON THE MANAGEMENT
OF THE AXILLA AT WARWICK BREAST UNIT, FOR WOMEN WITH
BREAST CANCER
L. Henderson*, H. Tafazal, S. Harries, L. Jones, D. Clarke. Warwick Hospital,
Warwick, UK.
Introduction: The Association of Breast Surgeons(ABS) recently published
guidelines on the management of the axilla. They state that in post-
menopausal patients with 2 sentinel nodes(SN) positive for macro-
metastasis, no further axillary treatment is required in those with disease
deemed low-risk of recurrence (T1, grade 1-2, ER positive/HER2 negative
and receiving whole breast radiotherapy).
Aim: determine if women with low-burden axillary disease would be
adversely affected by the implementation of the ABS guidelines.
Method: ABS guidelines were retrospectively applied to patients under-
going SN biopsy 2014e2015 at Warwick Hospital. Clinical data (demo-
graphics,tumour and lymph-node histology) was collated from electronic
records.
Result: Study group¼ 454 patients. 270 patients were postmenopausal. Of
these, 67(25%) patients were found to have macrometastasis in 1-2 SN. 17
of these 67 patients would have had no further axillary treatment based on
ABS guidelines. Of this group 13(76%) had no further disease on ANC, while
4(24%) were found to have disease in 3 lymph-nodes.
Conclusion: Following ABS recommendations, 76% of patients meeting
criteria for low-risk disease, had no further axillary disease. 24% were
found to have signiﬁcant axillary macrometastasis. We conclude that
almost a quarter of our patients may have been adversely affected by the
implementation of the ABS guidelines.http://dx.doi.org/10.1016/j.ijsu.2016.08.116
1043: ASSESSMENT OF THE EFFICACY OF AXILLARY USS AND CYTOLOGY
IN PREDICTING THE AXILLARY NODAL BURDEN IN PRIMARY BREAST
CANCER
L. Balance*, P. Asad, M. Bramley. North Manchester, North West, UK.
Abstracts / International Journal of Surgery 36 (2016) S31eS132S54Background: The National Institute of Clinical Excellence issued guide-
lines on Axillary Node Clearance (ANC) in patients with early and localised
primary breast cancer. A 2015 ABS Consensus statement explores how ANC
may be avoided. There is controversy in the management of patients with
low burden axillary disease as predicted from the Ultrasound (US) Scan.
Aim: To investigate the efﬁcacy of the US scan in identifying low burden
axillary disease in patients with primary breast cancer.
Method: A retrospective study was performed at a symptomatic breast
unit including all patients undergoing an ANC between January and
December 2014.
Result: A total of 112 patients had an ANC. All patients had an US Axilla.
72% had light burden disease on US scan (<3 nodes). 27 of these had 3 or
more positive nodes on ANC.
Conclusion: The majority of low burden disease identiﬁed from US scan
had a positive ANC. This suggests in symptomatic breast cancer that low
burden disease cannot always be predicted. Our current axillary man-
agement will be unchanged and we plan to conduct a prospective trial
having asked the radiologists to comment speciﬁcally on number of
involved nodes.http://dx.doi.org/10.1016/j.ijsu.2016.08.117
1256: ACCURACY OF INFORMATION ON SURGICAL MANAGEMENT OF
BREAST CANCER ON THE INTERNET
R. Waqar*, A. Oomman, N. Kirmani. Princess Alexandra Hospital, Harlow,
Essex, UK.
Aim: The aim of this study was to assess the accuracy and accessibility of
the information on the Surgical Management of Breast Cancer on the
internet.
Method: The contents of the top 100 websites from three different search
engines were selected. The quality of websites was evaluated using an
investigator-designed appraisal tool based on the guidelines from NICE,
Association of Breast Surgery and Good Surgical Practice.
Result: Reassuringly in 90% of the websites Surgical procedures like
‘Mastectomy’, ‘Breast conserving surgery’, ‘lymph node surgery’ and
‘breast reconstruction’ were discussed.Only 29% websites discussed
“Management of contralateral breast”.
Particular areas of weakness were the lack of information on management
of post-operative complications, surveillance and management of the
contralateral breast.
Conclusion: There appears to be a great variability in the quality of in-
formation present online on the surgical management of Breast cancer.
Grading of websites according to the accuracy of information they contain
may also enable healthcare professionals to signpost patients to trust-
worthy, up-to-date websites. There is an onus of the Royal College of
Surgeons and Surgical Associations to ensure that they invest in websites
that provide accurate information on the Surgical management of Breast
Cancer, so that nursing patients receive high quality information.http://dx.doi.org/10.1016/j.ijsu.2016.08.118Cardiothoracic surgery
0127: BLEEDING COMPLICATIONS IN AORTIC SURGERY WITH OR
WITHOUT APROTININ
A. Curtis 1,*, C. Rajakaruna 2. 1University of Bristol, Bristol, UK; 2Bristol Heart
Institute, Bristol, UK.
Aprotinin (Trasylol) may reduce bleeding complications in aortic surgery
but the evidence is limited and conﬂicting. There is also evidence that
aprotinin increases renal failure, stroke and mortality.
Aim: To determine whether aprotinin reduces bleeding complications in
adults undergoing aortic surgery.
Method: A single centre retrospective cohort study including 281
consecutive adult patients undergoing aortic surgery at the Bristol HeartInstitute. Of these, 105 (37.4%) received aprotinin and 176 (62.6%) did not.
The primary outcome was bleeding complication consisting of (i) post-
operative blood loss; (ii) transfusion requirements and (iii) haemoglobin
reduction. Secondary outcomes included systemic complications. Statis-
tical analysis was completed using the Mann Whitney U Test and Chi-
squared Test.
Result: Baseline characteristics and perioperative variables were similar
between the two groups. Total blood loss was only marginally lower
(p > 0.05) in the aprotinin group (750mL vs. 762.5mL) which didn't cause a
signiﬁcant difference in percentage haemoglobin reduction following
surgery (28.6% vs. 29.7%). There was also a non-signiﬁcant reduction in
blood product transfusions in the aprotinin group (52.4% vs. 59.1%).
Conclusion: This is the largest study to explore aprotinin use in aortic
surgery. Our results don't support the use of aprotinin in aortic surgery
with no signiﬁcant reduction in bleeding complications.http://dx.doi.org/10.1016/j.ijsu.2016.08.120
0172: MUCH ADO ABOUT NOTHING e ARE PATIENTS AWARE OF THE
MORTALITY DATA PUBLISHED BY THE SOCIETY OF CARDIOTHORACIC
SURGEONS?
J. Choi 1,*, R. Boix 2, J. Roxburgh 2, M. Sabetai 2. 1King's College London,
London, UK; 2Department of Cardiac Surgery, Guy's and St Thomas' NHS
Foundation Trust, London, UK.
Objective: Surgeon-speciﬁc mortality data (SSMD) in cardiac surgery
appeared in the public domain in 2007. However, there is no clear indi-
cation that the public appreciates or engages with these data. Our aimwas
to assess patient awareness and interpretation of the Society of Cardio-
thoracic Surgeons (SCTS) data on SSMD and hospital-speciﬁc mortality
data (HSMD).
Method: A questionnaire consisting of 17 questions, including SSMD and
HSMD published from 2010 to 2013 by the SCTS, was interpreted by 42
cardiac patients, 4 days post-operatively.
Result: No patients were aware of the HSMD and only 7% (3/42) of the
patients were aware of the SSMD published on the SCTS website. 83% (35/
42) of patients interpreted the SSMD correctly. Although these data only
mattered to 38%(16/42) of patients, 50% (21/42) would appreciate a dis-
cussion about the mortality data, prior to their operation.
Conclusion: Our study showed very little patient awareness of the SCTS
data. However, themajority of patients were able to interpret themortality
data and there was willingness to engage - patients care about results.
Therefore we pose the question e is it worth the SCTS investing in
increasing patient awareness or should we be using this data solely for
monitoring purposes?http://dx.doi.org/10.1016/j.ijsu.2016.08.121
0295: AORTIC REGURGITATION INCREASES WITH DURATION
FOLLOWING HEARTWARE HVAD IMPLANTATION
V. Naruka 2,*, S. Tsui 1, S. Pettit 1, C. Lewis 1. 1 Papworth Hospital NHS
Foundation Trust, Cambridge, UK; 2University of Cambridge and Papworth
Hospital NHS Foundation Trust, Cambridge, UK.
Aim: Patient survival and performance of continuous-ﬂow left ventricular
assist devices (CF LVAD) are adversely affected by aortic regurgitation (AR).
We examined the development of AR during HeartWare HVAD support.
Method: We reviewed records of 56 consecutive patients after HVAD
implantation between 2009 and 2015. Aortic valve (AV) opening was
encouraged by optimisation of LVAD speed and use of the Lavare cycle in
all patients.
Result: At LVAD implant: 2 patients required bioprosthetic AV
replacement (AVR); 12 had mild AR. During LVAD support: 18 patients
had no AR or resolution of mild AR. De novo mild AR developed in 22
patients. Moderate AR developed in 13 (10 de novo, 3 from pre-LVAD
mild AR). Severe AR developed in 2 (1 de novo, 1 from pre-LVAD mild
AR), both underwent urgent transplantation. Kaplan-Meier survival
